Moderna stock heads into November 6 results with oncology focus

Published on 11/01/2026 at 17:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock heads into a November 6 earnings report as investors assess vaccine sales and the company’s oncology strategy. Analysts expect a $891.34 million revenue quarter.

Moderna Heads Into Key Results

Moderna is expected to release third-quarter results before the market opens on Friday, November 6.
The earnings update will test whether seasonal vaccine sales can support the company after a weak second quarter.
Investors are also watching whether Moderna's oncology pipeline can translate positive clinical data into future commercial growth.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna is expected to report its third-quarter 2026 results before the market opens on Friday, November 6. MarketBeat cites analyst expectations for revenue of 891.34 million US dollars and a loss of 1.11 US dollars per share.

Results Put Vaccine Sales In Focus

The report will follow a second quarter in which Moderna posted revenue of 145 million US dollars and a loss of 1.97 US dollars per share. MarketBeat said quarterly revenue was 2.1 percent above the year-earlier period, while analysts had expected revenue of 102.93 million US dollars.

Oncology Raises The Longer-Term Stakes

Investor attention also remains on Moderna’s personalized cancer-vaccine program. Positive clinical-trial data have strengthened interest in the oncology pipeline, but the November report will keep near-term attention on revenue, losses and the company’s ability to turn vaccine demand into cash flow.

Moderna stock traded at 197.88 euros on Lang & Schwarz at 17:15 CET on Sunday, November 1, 2026; investors can follow the real-time quote of Moderna stock.